For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...

the right inhaler for the right person. There are various problems in administering asthma and COPD treatment to patients. In asthma, for example, people don't necessarily perceive that they have ...

Long-term inhaled corticosteroid (ICS) use for chronic obstructive pulmonary disease/ COPD (lung disease) may increase the ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD: Paris Saturday, March 29, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour an ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Chronic obstructive pulmonary disease (COPD) is among the most common breathing conditions. It's the result of damaged lung tissue.

Treatments for COPD can include lifestyle changes, oral and inhaled medicines, oxygen therapy, and surgery. Though there’s no cure for the condition, you can manage the symptoms. Follow your ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...